PL-9
The intermediate of prulifloxacin
Molecular Formular: C14H11F2NO3S
Modecular Weight: 311.3
Welcome to contact: +86 18046216202 (Jessica)
+86 592 5789920 (Office Line)
*The following content is generated by AI and is for reference only.
Ethyl 6,7-difluoro-1-methyl-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylate is a sophisticated heterocyclic compound belonging to the class of fluoroquinolone antibiotics. This molecule features a unique fused thiazeto ring system attached to a quinoline core, distinguished by fluorine substitutions at the 6 and 7 positions and a methyl group on the nitrogen atom at position 1. While specific commercial catalog numbers vary by supplier, this structure represents a key intermediate or analog in the development of advanced antimicrobial agents designed to overcome bacterial resistance mechanisms.
The primary utility of such compounds lies in their potential application as broad-spectrum antibacterial agents. The presence of the difluoro moiety typically enhances lipophilicity and membrane permeability, allowing the drug to penetrate bacterial cell walls more effectively. Furthermore, the modification of the C-7 position with a fused heterocyclic ring often improves binding affinity to DNA gyrase and topoisomerase IV, the essential enzymes targeted by fluoroquinolones to inhibit bacterial DNA replication. Consequently, derivatives of this scaffold are investigated for treating resistant Gram-negative and Gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA) or multidrug-resistant Pseudomonas aeruginosa.
In pharmaceutical research, this chemical serves as a vital building block for synthesizing next-generation quinolone derivatives. Its synthesis involves complex organic reactions, including cyclization and halogenation steps, requiring precise control over reaction conditions to ensure high purity and stereochemical integrity. Although it may not yet be a widely marketed final therapeutic product, its structural profile offers significant promise for medicinal chemists aiming to optimize pharmacokinetic properties and reduce toxicity associated with older generation fluoroquinolones. As antibiotic resistance continues to escalate globally, the exploration of novel scaffolds like this thiazeto-quinoline hybrid remains critical for public health innovation. Researchers utilize this compound to study structure-activity relationships (SAR), guiding the design of safer and more potent antibiotics capable of addressing emerging infectious disease threats.